MX2019007156A - Inhibidores de imidazopirazina de la tirosina cinasa de bruton. - Google Patents
Inhibidores de imidazopirazina de la tirosina cinasa de bruton.Info
- Publication number
- MX2019007156A MX2019007156A MX2019007156A MX2019007156A MX2019007156A MX 2019007156 A MX2019007156 A MX 2019007156A MX 2019007156 A MX2019007156 A MX 2019007156A MX 2019007156 A MX2019007156 A MX 2019007156A MX 2019007156 A MX2019007156 A MX 2019007156A
- Authority
- MX
- Mexico
- Prior art keywords
- imidazopyrazine
- bruton
- inhibitors
- tyrosine kinase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de Fórmula (I) y (II) o una sal farmacéuticamente aceptable de los mismos, o a composiciones farmacéuticas que comprenden estos compuestos y a su uso en terapia. En particular, en algunas modalidades, la presente invención se refiere a los compuestos de Fórmula (I) y (II), composiciones farmacéuticas de los mismos, y al uso de los compuestos y composiciones farmacéuticas en el tratamiento de un trastorno hiperproliferativo, un trastorno inflamatorio, un trastorno inmune, o un trastorno autoinmune.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437633P | 2016-12-21 | 2016-12-21 | |
| US201762569028P | 2017-10-06 | 2017-10-06 | |
| PCT/IB2017/058319 WO2018116259A1 (en) | 2016-12-21 | 2017-12-21 | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007156A true MX2019007156A (es) | 2019-09-05 |
Family
ID=60972291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007156A MX2019007156A (es) | 2016-12-21 | 2017-12-21 | Inhibidores de imidazopirazina de la tirosina cinasa de bruton. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10858364B2 (es) |
| EP (1) | EP3558968B1 (es) |
| JP (1) | JP7022131B2 (es) |
| KR (1) | KR102559851B1 (es) |
| CN (1) | CN110291080B (es) |
| AU (1) | AU2017383236B2 (es) |
| BR (1) | BR112019012604A2 (es) |
| CA (1) | CA3046578A1 (es) |
| CL (1) | CL2019001674A1 (es) |
| ES (1) | ES2856248T3 (es) |
| IL (1) | IL267374B (es) |
| MX (1) | MX2019007156A (es) |
| SA (1) | SA519402217B1 (es) |
| WO (1) | WO2018116259A1 (es) |
| ZA (1) | ZA201903932B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CA3005727A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators |
| PE20230731A1 (es) | 2015-12-22 | 2023-05-03 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| PE20190731A1 (es) | 2016-06-20 | 2019-05-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| HRP20230090T1 (hr) | 2018-03-30 | 2023-03-17 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| US11040031B2 (en) | 2018-06-18 | 2021-06-22 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
| PE20230407A1 (es) | 2019-11-11 | 2023-03-07 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| CN114807038B (zh) * | 2022-02-11 | 2023-11-10 | 四川大学华西第二医院 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2081435T3 (en) * | 2006-09-22 | 2016-08-15 | Pharmacyclics Llc | INHIBITORS OF BRUTON'S TYROSINKINASE |
| AU2010238361B2 (en) * | 2009-04-16 | 2015-08-06 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Imidazopyrazines for use as kinase inhibitors |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| CA2841887A1 (en) * | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors |
| HUE041987T2 (hu) * | 2011-07-19 | 2019-06-28 | Merck Sharp & Dohme | 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók |
| BR112016012794A2 (pt) * | 2013-12-05 | 2017-08-08 | Acerta Pharma Bv | Combinação terapêutica de um inibidor de pi3k e um inibidor de btk |
| WO2015110923A2 (en) * | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| TW201618774A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法 |
| WO2016106623A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
| WO2016106627A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| US20180305348A1 (en) | 2015-06-02 | 2018-10-25 | Pharmacyclics Llc | Inhibitors of brutons tyrosine kinase |
-
2017
- 2017-12-21 CA CA3046578A patent/CA3046578A1/en active Pending
- 2017-12-21 JP JP2019533229A patent/JP7022131B2/ja active Active
- 2017-12-21 US US16/448,056 patent/US10858364B2/en active Active
- 2017-12-21 CN CN201780086892.3A patent/CN110291080B/zh active Active
- 2017-12-21 AU AU2017383236A patent/AU2017383236B2/en active Active
- 2017-12-21 MX MX2019007156A patent/MX2019007156A/es unknown
- 2017-12-21 BR BR112019012604A patent/BR112019012604A2/pt active Search and Examination
- 2017-12-21 WO PCT/IB2017/058319 patent/WO2018116259A1/en unknown
- 2017-12-21 KR KR1020197020718A patent/KR102559851B1/ko active IP Right Grant
- 2017-12-21 ES ES17829328T patent/ES2856248T3/es active Active
- 2017-12-21 EP EP17829328.8A patent/EP3558968B1/en active Active
-
2019
- 2019-06-16 IL IL267374A patent/IL267374B/en unknown
- 2019-06-18 ZA ZA2019/03932A patent/ZA201903932B/en unknown
- 2019-06-18 CL CL2019001674A patent/CL2019001674A1/es unknown
- 2019-06-19 SA SA519402217A patent/SA519402217B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102559851B1 (ko) | 2023-07-25 |
| AU2017383236B2 (en) | 2022-02-10 |
| AU2017383236A1 (en) | 2019-06-27 |
| IL267374A (en) | 2019-08-29 |
| EP3558968B1 (en) | 2021-02-03 |
| CN110291080A (zh) | 2019-09-27 |
| ES2856248T3 (es) | 2021-09-27 |
| CN110291080B (zh) | 2022-07-08 |
| CA3046578A1 (en) | 2018-06-28 |
| EP3558968A1 (en) | 2019-10-30 |
| ZA201903932B (en) | 2021-01-27 |
| IL267374B (en) | 2021-07-29 |
| BR112019012604A2 (pt) | 2019-11-26 |
| WO2018116259A1 (en) | 2018-06-28 |
| US20190345164A1 (en) | 2019-11-14 |
| JP2020514264A (ja) | 2020-05-21 |
| KR20190095403A (ko) | 2019-08-14 |
| CL2019001674A1 (es) | 2019-11-08 |
| JP7022131B2 (ja) | 2022-02-17 |
| US10858364B2 (en) | 2020-12-08 |
| SA519402217B1 (ar) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| EA201790951A1 (ru) | Производные гидроксиалкилзамещенного фенилтриазола и их применение | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| NZ722326A (en) | Tricyclic compounds as anticancer agents | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| EA201891050A1 (ru) | Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| PH12019501999A1 (en) | Pyrazole derivatives as bromodomain inhibitors | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2020000402A (es) | Nuevos derivados de xantina sustituidos. | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| MX2021015333A (es) | Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| EA201991456A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы брутона |